Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Kiniksa Pharmaceuticals Ltd (KNSA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 956,654
  • Shares Outstanding, K 54,142
  • Annual Sales, $ 0 K
  • Annual Income, $ -64,870 K
  • 36-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.74
  • Number of Estimates 2
  • High Estimate -0.62
  • Low Estimate -0.85
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.50 +6.79%
on 02/05/19
25.79 -31.68%
on 01/23/19
-7.02 (-28.49%)
since 01/22/19
3-Month
16.50 +6.79%
on 02/05/19
28.90 -39.03%
on 12/31/18
-2.67 (-13.16%)
since 11/21/18

Most Recent Stories

More News
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa", "we", and "our") announced today the pricing of its public offering of 2,654,984 Class A common shares at a public offering price of $18.26 per...

KNSA : 17.62 (-0.28%)
Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering and Concurrent Private Placement

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa," "we," and "our") announced today that it is commencing a public offering of 8,000,000 Class A common shares. In addition, Kiniksa expects to grant...

KNSA : 17.62 (-0.28%)
Kiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa"), a biopharmaceutical company with a pipeline of five product candidates across various stages of development, today announced an active investigational...

KNSA : 17.62 (-0.28%)
5 Best-Performing IPOs of 2018

Strong economic fundamentals and increased foreign investment have led to such a high number of companies going public.

KNSA : 17.62 (-0.28%)
ALLK : 37.68 (+7.17%)
BJ : 25.87 (+1.49%)
TLRY : 79.07 (-0.16%)
COLD : 29.44 (+3.15%)
EQH : 19.34 (+0.26%)
Kiniksa Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 37 Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 3:30 p.m. Pacific Time / 6:30 p.m. Eastern...

KNSA : 17.62 (-0.28%)
JPM : 105.00 (-0.45%)
Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data and Initiates Pivotal Phase 3 Clinical Trial

- Phase 2 enrollment completed; interim clinical data show reductions in both inflammation and reported pain after first dose and throughout treatment period

KNSA : 17.62 (-0.28%)
Kiniksa Provides Update on U.S. FDA Review of Investigational New Drug Application for Mavrilimumab in Giant Cell Arteritis

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa"), a biopharmaceutical company with a pipeline consisting of five product candidates across various stages of development, focused on autoinflammatory...

KNSA : 17.62 (-0.28%)
Detailed Research: Economic Perspectives on Knight-Swift Transportation, Benitec Biopharma, Eastern, Kiniksa Pharmaceuticals, Qualstar, and Nomura Holdings Inc ADR -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Knight-Swift Transportation...

KNSA : 17.62 (-0.28%)
NMR : 3.96 (-1.00%)
KNX : 33.60 (-1.73%)
BNTC : 1.65 (+5.77%)
EML : 26.97 (+1.77%)
BNIKF : 0.0810 (-12.43%)
QBAK : 6.51 (-1.06%)
Kiniksa Reports Third Quarter 2018 Financial Results and Pipeline Progress

- Rilonacept pivotal Phase 3 clinical trial initiating this year

KNSA : 17.62 (-0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More Share

Trade KNSA with:

Business Summary

Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd. is based in Massachusetts,...

See More

Key Turning Points

2nd Resistance Point 18.21
1st Resistance Point 17.91
Last Price 17.62
1st Support Level 17.38
2nd Support Level 17.15

See More

52-Week High 32.88
Fibonacci 61.8% 25.30
Fibonacci 50% 22.96
Fibonacci 38.2% 20.62
Last Price 17.62
52-Week Low 13.04

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar